Get the Stockscreener App
6.805
5.57%
-0.375
Precision Biosciences Inc stock is traded at $6.805, with a volume of 87,824.
It is down -5.57% in the last 24 hours and down -23.13% over the past month.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
See More
Previous Close:
$7.18
Open:
$7.07
24h Volume:
87,824
Relative Volume:
1.24
Market Cap:
$54.89M
Revenue:
$52.29M
Net Income/Loss:
$-73.52M
P/E Ratio:
-8.4012
EPS:
-0.81
Net Cash Flow:
$-100.45M
1W Performance:
-11.95%
1M Performance:
-23.13%
6M Performance:
-48.05%
1Y Performance:
-46.15%
1-Day Range:
$6.77
$7.12
1-Week Range:
$6.77
$7.77
52-Week Range:
$6.77
$19.43
Precision Biosciences Inc Stock (DTIL) Company Profile
Name
Precision Biosciences Inc
Sector
Industry
Phone
919-314-5512
Address
302 EAST PETTIGREW STREET, DURHAM, NC
Compare DTIL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| DTIL | 6.825 | 54.89M | 52.29M | -73.52M | -100.45M | -0.81 |
| VRTX | 448.26 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 745.57 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 588.39 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.72 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.24 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-30-24 | Initiated | Guggenheim | Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Jun-09-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-27-20 | Resumed | BTIG Research | Buy |
| Apr-03-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-05-20 | Initiated | Stifel | Buy |
| Feb-25-20 | Initiated | William Blair | Outperform |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jul-16-19 | Initiated | H.C. Wainwright | Buy |
| Apr-22-19 | Initiated | Barclays | Overweight |
| Apr-22-19 | Initiated | Goldman | Buy |
| Apr-22-19 | Initiated | JP Morgan | Overweight |
| Apr-22-19 | Initiated | Jefferies | Buy |
View All
Precision Biosciences Inc Stock (DTIL) Latest News
Precision BioSciences to Participate in Upcoming November Investor Conferences - BioSpace
Precision BioSciences to Present at Two Major Gene Editing Conferences in November | DTIL Stock News - StockTitan
Trading (DTIL) With Integrated Risk Controls - Stock Traders Daily
Gene Editing Tools Market Size, Growth Opportunities, - openPR
Precision BioSciences Reports 99% HBV Gene Editing Success, Unveils Phase 1 Trial Design | DTIL Stock News - StockTitan
JANUS HENDERSON GROUP PLC's Strategic Acquisition in Precision B - GuruFocus.com
Precision BioSciences stock hits 52-week low at $7.94 By Investing.com - Investing.com Canada
Precision BioSciences stock hits 52-week low at $7.94 - Investing.com
Highbridge Capital Management's Strategic Acquisition of Precisi - GuruFocus.com
What is HC Wainwright's Forecast for DTIL FY2024 Earnings? - MarketBeat
Research Analysts Offer Predictions for DTIL FY2027 Earnings - MarketBeat
(DTIL) Technical Data - Stock Traders Daily
Precision Biosciences CEO Michael Amoroso sells shares worth $24,668 - Investing.com India
Precision Biosciences' general counsel sells $4,815 in stock - Investing.com
Precision Biosciences' general counsel sells $4,815 in stock By Investing.com - Investing.com UK
Precision BioSciences keeps $34 target, Market Perform rating By Investing.com - Investing.com Australia
Precision BioSciences: Q3 Earnings Snapshot - Darien Times
Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update - BioSpace
Precision BioSciences keeps $34 target, Market Perform rating - Investing.com
Precision BioSciences (DTIL) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Precision BioSciences (DTIL) Surges 6.1%: Is This an Indication of Further Gains? - MSN
Precision BioSciences Announces FDA Accepts IND for PBCAR19B, a Next-Generation, Stealth Cell, CD19 Allogeneic CAR T Candidate for Non-Hodgkin Lymphoma - Marketscreener.com
Precision BioSciences (DTIL) Set to Announce Earnings on Monday - MarketBeat
Precision BioSciences to Report Third Quarter Results on November 4, 2024 - BioSpace
Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024 - Business Wire
(DTIL) Trading Report - Stock Traders Daily
Precision BioSciences stock hits 52-week low at $8.22 By Investing.com - Investing.com Canada
500: Something went wrong - Investing.com
Precision BioSciences stock hits 52-week low at $8.22 - Investing.com India
Precision BioSciences begins clinical trial for hepatitis B cure By Investing.com - Investing.com Australia
Precision BioSciences touts gene editing efficiency with ARCUS - Investing.com India
Precision BioSciences touts gene editing efficiency with ARCUS By Investing.com - Investing.com Canada
Precision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual Congress - Business Wire
Precision BioSciences to Report Q3 Earnings: What's in the Cards? - Yahoo Finance
Precision BioSciences, Inc. announced that it has received $25.65 million in funding from a group of investors. - Marketscreener.com
Precision BioSciences begins clinical trial for hepatitis B cure - Investing.com
Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B - Business Wire
Precision BioSciences Advances Gene Editing Trials Globally - TipRanks
Precision BioSciences to Participate in Upcoming Longwood Boston CEO and Guggenheim Healthcare Conferences - BioSpace
Short Interest in Precision BioSciences, Inc. (NASDAQ:DTIL) Drops By 7.1% - MarketBeat
Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress - BioSpace
Precision Biosciences Inc Stock (DTIL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Precision Biosciences Inc Stock (DTIL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Scimeca Dario | General Counsel and Secretary |
Nov 04 '24 |
Sale |
8.19 |
588 |
4,816 |
7,969 |
| Amoroso Michael | President and CEO |
Nov 04 '24 |
Sale |
8.19 |
3,012 |
24,668 |
28,537 |
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):